These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34162728)

  • 21. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
    Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
    Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
    Rhodes JM; Mato AR
    Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Integrin Signaling Shaping BTK-Inhibitor Resistance.
    Polcik L; Dannewitz Prosseda S; Pozzo F; Zucchetto A; Gattei V; Hartmann TN
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
    Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
    Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia.
    Kong C; Wu M; Lu Q; Ke B; Xie J; Li A
    Leuk Res; 2024 Sep; 144():107548. PubMed ID: 39018782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia.
    Cuesta-Mateos C; López-Giral S; Alfonso-Pérez M; de Soria VG; Loscertales J; Guasch-Vidal S; Beltrán AE; Zapata JM; Muñoz-Calleja C
    Exp Hematol; 2010 Sep; 38(9):756-64, 764.e1-4. PubMed ID: 20488224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative analysis of normal versus CLL B-lymphocytes reveals patient-specific variability in signaling mechanisms controlling LFA-1 activation by chemokines.
    Montresor A; Bolomini-Vittori M; Simon SI; Rigo A; Vinante F; Laudanna C
    Cancer Res; 2009 Dec; 69(24):9281-90. PubMed ID: 19934331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
    Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
    Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
    Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
    Xia M; Luo TY; Shi Y; Wang G; Tsui H; Harari D; Spaner DE
    J Immunol; 2020 Nov; 205(10):2629-2639. PubMed ID: 33067379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
    Danilov AV
    Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
    Ten Hacken E; Burger JA
    Biochim Biophys Acta; 2016 Mar; 1863(3):401-413. PubMed ID: 26193078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia.
    Patton JT; Woyach JA
    Semin Hematol; 2024 Apr; 61(2):100-108. PubMed ID: 38749798
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy.
    Alsadhan A; Chen J; Gaglione EM; Underbayev C; Tuma PL; Tian X; Freeman LA; Baskar S; Nierman P; Soto S; Itsara A; Ahn IE; Sun C; Bibikova E; Hartmann TN; Mhibik M; Wiestner A
    Clin Cancer Res; 2023 Sep; 29(18):3612-3621. PubMed ID: 37227160
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
    Patel VK; Lamothe B; Ayres ML; Gay J; Cheung JP; Balakrishnan K; Ivan C; Morse J; Nelson M; Keating MJ; Wierda WG; Marszalek JR; Gandhi V
    Leukemia; 2018 Apr; 32(4):920-930. PubMed ID: 29099493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.
    Dias AL; Jain D
    Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):265-71. PubMed ID: 24433470
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects.
    Eiken AP; Smith AL; Skupa SA; Schmitz E; Rana S; Singh S; Kumar S; Mallareddy JR; de Cubas AA; Krishna A; Kalluchi A; Rowley MJ; D'Angelo CR; Lunning MA; Bociek RG; Vose JM; Natarajan A; El-Gamal D
    Cancer Res Commun; 2024 May; 4(5):1328-1343. PubMed ID: 38687198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion.
    Yin S; Gambe RG; Sun J; Martinez AZ; Cartun ZJ; Regis FFD; Wan Y; Fan J; Brooks AN; Herman SEM; Ten Hacken E; Taylor-Weiner A; Rassenti LZ; Ghia EM; Kipps TJ; Obeng EA; Cibulskis CL; Neuberg D; Campagna DR; Fleming MD; Ebert BL; Wiestner A; Leshchiner I; DeCaprio JA; Getz G; Reed R; Carrasco RD; Wu CJ; Wang L
    Cancer Cell; 2019 Feb; 35(2):283-296.e5. PubMed ID: 30712845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody.
    Mateu-Albero T; Juárez-Sánchez R; Loscertales J; Mol W; Terrón F; Muñoz-Calleja C; Cuesta-Mateos C
    Cancer Immunol Immunother; 2022 Mar; 71(3):627-636. PubMed ID: 34297159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
    ten Hacken E; Burger JA
    Pharmacol Ther; 2014 Dec; 144(3):338-48. PubMed ID: 25050922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.